[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-endometritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-endometritis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,38,64,92],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":4},"100643715","gnrh-agonist-pretreatment-in-persistent-chronic-endometritis-undergoing-fet-100643715",false,"NCT07642700","GnRH Agonist Pretreatment in Persistent Chronic Endometritis Undergoing FET","Association of GnRH Agonist Pretreatment With Pregnancy Outcomes in Women With Persistent Chronic Endometritis Undergoing Frozen Embryo Transfer","Inclusion Criteria:\n\n* Aged 20-40 years; confirmed persistent chronic endometritis (PCE) via hysteroscopy plus CD138 immunohistochemistry, defined as positive endometrial pathology after two-course antibiotic treatment for CE.\n* Frozen-thawed embryo transfer (FET) with available transferable cleavage-stage or blastocyst embryos from IVF\u002FICSI cycles.\n* No acute pelvic infection at enrollment; ≥1 month elapsed after completion of last antibiotic therapy for endometritis.\n* Normal uterine cavity except for inflammatory changes of PCE; no severe uterine malformation or severe intrauterine adhesion requiring surgical intervention.\n* Voluntarily sign informed consent and complete full follow-up of pregnancy outcomes\n\nExclusion Criteria:\n\n* History of pelvic tuberculosis, intrauterine adhesions, submucous uterine myoma or endometrial polyp before FET\n* Uncontrolled systemic endocrine disorders, autoimmune diseases (APS, SLE), severe hepatic\u002Frenal\u002Fcardiopulmonary dysfunction.\n* Known allergy to GnRH agonist for down-regulation regimen; prior long-acting GnRH-a intolerance.\n* Recent use of immunosuppressant, long-term glucocorticoid or drugs interfering endometrial development within 3 months before enrollment.\n* Lost to follow-up or plan to abandon embryo transfer after enrollment.","FEMALE","20 Years","40 Years",{"count":20,"type":21},150,"ESTIMATED","OBSERVATIONAL","Women with PCE represent a treatment-resistant phenotype in whom the endometrial inflammatory and immune status remains abnormal despite antibiotic therapy. GnRH agonist pretreatment may be most beneficial in endometrial phenotypes marked by persistent or residual inflammatory impairment rather than in all frozen embryo transfer populations.We therefore conducted a single-center prospective cohort study to investigate whether GnRH-HRT, compared with non-GnRH-based preparations, improve clinical pregnancy and live birth in women with PCE undergoing FET,",[25],"Chronic Endometritis","NOT_YET_RECRUITING","2026-06-10",{"date":29,"type":30},"2026-06-11","ACTUAL",{"date":32,"type":21},"2026-06-01",{"date":34,"type":21},"2028-06-01",{"name":36,"class":37},"Guoxia Yang","OTHER",{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":45,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":63},"100630536","doxycycline-and-progestin-therapy-for-chronic-endometritisce-in-patients-with-recurrent-reproductive-failurerrf-100630536","NCT07488949","Doxycycline and Progestin Therapy for Chronic Endometritis(CE) in Patients With Recurrent Reproductive Failure(RRF)","Clinical Efficacy and Pregnancy Outcomes of Doxycycline Combined With Medroxyprogesterone Acetate Therapy for Chronic Endometritis(CE) in Patients With Recurrent Reproductive Failure(RRF): A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* women aged 20-45 years;\n* plans to conceive within 12 months;\n* chronic endometritis(CE) confirmed by endometrial CD138 immunohistochemistry (IHC);\n* a diagnosis of recurrent reproductive failure(RRF);\n* willingness to undergo hysteroscopy and endometrial biopsy;\n* no contraindications to the study medications.\n\nExclusion Criteria:\n\n* acute genital tract infection, gynecologic malignancy, endometrial hyperplasia, or uterine fibroids;\n* pregnancy or lactation;\n* contraindications to hysteroscopy or anesthesia;\n* use of antibiotics, glucocorticoids, estrogens, or progestins within 3 months before trial initiation;\n* allergy to doxycycline or medroxyprogesterone acetate(MPA);\n* abnormal semen parameters in the male partner.","45 Years",{"count":47,"type":21},1000,"INTERVENTIONAL",[50],"NA","A Prospective Randomized Controlled Trial, the goal of this clinical trial is to evaluate the efficacy and safety of doxycycline alone versus doxycycline plus medroxyprogesterone acetate (MPA) in women with chronic endometritis (CE), and to assess subsequent reproductive outcomes. Participants will be randomly assigned to one of two groups and will receive the assigned treatment. Participants will be followed for reproductive outcomes, including pregnancy , ongoing pregnancy, spontaneous miscarriage, and live birth.",[25],"RECRUITING","2026-03-18",{"date":56,"type":30},"2026-03-23",{"date":58,"type":30},"2024-04-09",{"date":60,"type":21},"2031-12-31",{"name":62,"class":37},"Fang Wang",1,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":72,"targetDuration":4,"studyType":48,"phases":74,"briefSummary":76,"conditions":77,"keywords":78,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":63},"100630297","phase-4-fuke-qianjin-capsule-plus-antibiotics-for-chronic-endometritis-100630297","NCT07485842","FuKe Qianjin Capsule Plus Antibiotics for Chronic Endometritis","Randomized, Double-Blind, Single-Simulation, Multicenter Clinical Study Evaluating the Efficacy and Safety of FuKe Qianjin Capsules in Combination With Antibiotics for the Treatment of Chronic Endometritis.","FKQJCE","Inclusion Criteria:\n\n1. Age range: 20 years old ≤ age ≤ 40 years old;\n2. Meets the diagnostic criteria for chronic endometritis;\n3. Meets the Traditional Chinese Medicine(TCM) syndrome differentiation criteria for damp-heat with deficiency of both qi and blood;\n4. Has a regular menstrual cycle, with a cycle length ≥21 days and ≤35 days;\n5. Voluntarily participates and signs the informed consent form.\n\nExclusion Criteria:\n\n1. Patients with concurrent acute genital tract and pelvic infections, etc.\n2. Patients with endometrial tuberculosis, endometrial cancer, or other malignant gynecological tumors.\n3. Patients with endometrial lesions, such as endometrial hyperplasia, uterine cavity adhesions, submucosal fibroids, or endometrial polyps.\n4. Patients with hydrosalpinx or pelvic abscesses.\n5. Patients with severe abnormalities in heart, liver, or kidney function.\n6. Patients with uncontrolled autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis, etc.).\n7. Patients with uncontrolled endocrine or metabolic diseases (e.g., diabetes, hyperthyroidism, or hypothyroidism, etc.).\n8. Patients with mental disorders (e.g., severe depression, schizophrenia) or unable to comply with follow-up.\n9. Pregnant or breastfeeding women, or those refusing contraception during treatment.\n10. Patients with allergies to study drugs (including Chinese herbal components or antibiotics).\n11. Patients who have participated in other clinical trials within the past 3 months.\n12. Other situations where the investigator deems the patient unsuitable for participation in the study.",{"count":73,"type":21},300,[75],"PHASE4","This randomized, double-blind, single-dummy, multicenter clinical study, led by Principal Investigator Xue Fengxia at Tianjin Medical University General Hospital (sponsor and primary trial institution) and funded by Zhuzhou Qianjin Pharmaceutical Co., Ltd., evaluates the safety and efficacy of FuKe Qianjin Capsules combined with standard antibiotic therapy for chronic endometritis (CE) in women aged 20-40 years. CE, a common gynecological inflammation marked by uterine plasma cell infiltration from bacterial infection, is linked to infertility, repeated implantation failure (RIF), and recurrent miscarriage (RM); it is often underdiagnosed due to non-specific symptoms, and first-line doxycycline therapy is limited by antibiotic resistance and high recurrence. FuKe Qianjin Capsules, a nationally recognized Chinese herbal medicine for gynecological inflammations, align with traditional Chinese medicine (TCM) treatment principles for CE (damp-heat stasis with qi and blood deficiency) and reduce antibiotic resistance per domestic research.\n\nApproximately 300 eligible participants (confirmed CE via hysteroscopy\u002Fpathology, matching TCM syndrome, regular menstrual cycles, informed consent) will be enrolled across 10-15 Chinese centers, with exclusion for acute infections, gynecological malignancies\u002F severe uterine lesions, organ dysfunction, uncontrolled systemic diseases, pregnancy\u002Flactation, drug hypersensitivity, or recent trial participation. All receive 14 days of oral doxycycline (100mg twice daily) and are randomized 1:1 to two double-blind groups (150 each): Experimental Group (56 days of FuKe Qianjin Capsules, 0.4g\u002Fcapsule, 2 capsules three times daily) or Control Group (56 days of matched capsule placebo).\n\nThe study includes a 28-day screening period, 56-day treatment phase, and 6-month post-treatment follow-up (in-person visits at Day 28±5\u002F56±7; telephone\u002Foutpatient follow-up at 3\u002F6 months). Efficacy assessments (hysteroscopy, TCM scoring, ultrasound), safety monitoring (vital signs, blood work, pregnancy testing), adverse event recording, and medication adherence checks occur at all visits, with ultrasound-confirmed clinical pregnancy rate as the key post-treatment outcome.\n\nThe team monitors known drug adverse effects (mild gastrointestinal\u002Fskin\u002Fneurological symptoms for the capsules; gastrointestinal\u002Fphotosensitivity\u002Frare liver\u002Fblood issues for doxycycline) and hysteroscopy risks (mild bleeding, rare perforation), with emergency protocols in place. Participants may withdraw voluntarily at any time with no impact on regular care; all data\u002Fspecimens are confidential, de-identified, and used only for study research (no commercial use).\n\nOverseen by the hospital's Institutional Ethics Committee and compliant with national research standards, the study's primary goal is to confirm the combined regimen's superior safety and efficacy over antibiotic monotherapy for CE, as well as its ability to improve reproductive outcomes and reduce recurrence. A positive result will establish this integrated Chinese-Western medicine approach as an evidence-based CE treatment, reducing antibiotic resistance and enhancing reproductive health for affected women, especially those with infertility, RIF, or recurrent miscarriage.",[25],[25,79,80,81,82],"Clinical efficacy and safety","Combination Drug Therapy","Multicenter Clinical Studies","Fuke Qianjin Capsule","2026-03-17",{"date":85,"type":30},"2026-03-20",{"date":87,"type":21},"2026-04",{"date":89,"type":21},"2027-12",{"name":91,"class":37},"Tianjin Medical University",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":48,"phases":100,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":63},"100606823","phase-1-randomized-controlled-trial-of-berberine-in-combination-with-doxycycline-in-the-treatment-of-chronic-endometritis-100606823","NCT07180563","Randomized Controlled Trial of Berberine in Combination With Doxycycline in the Treatment of Chronic Endometritis","Inclusion Criteria:\n\nDiagnosis of chronic endometritis by CD138 immunohistochemistry; Age≥ 20 years old, females of childbearing age; Agree to undergo hysteroscopy and hysteroscopic endometrial biopsy; No serious systemic disease; There are no contraindications to oral administration of doxycycline hydrochloride and berberine hydrochloride.\n\nExclusion Criteria:\n\nPatients with pregnancy status, uterine malignant disease, hormone therapy within 3 months, glucose-6 phosphate dehydrogenase deficiency, hemolytic anemia, hypersensitivity to berberine hydrochloride or doxycycline. In addition, berberine hydrochloride has fewer oral adverse reactions, occasional nausea and vomiting, rash and drug fever, which disappear after stopping the drug. If the patient takes the wrong or missed medication, it is excluded.",{"count":99,"type":21},206,[101,102],"PHASE1","PHASE2","Study Subjects: Eligible patients were initially diagnosed with chronic endometritis (CE) by CD138 testing through outpatient hysteroscopy. Positive CD138 expression is defined as at least one or more positive-staining plasma cells per 10 high-power fields identified as positive, and less than one positive-stained plasma cell identified as negative \\[8\\]. All patients signed an informed consent form prior to participating in the study, and the study followed the principles of the Declaration of Helsinki.\n\nInclusion Criteria: Diagnosis of chronic endometritis by CD138 immunohistochemistry; Age≥ 20 years old, females of childbearing age; Agree to undergo hysteroscopy and hysteroscopic endometrial biopsy; No serious systemic disease; There are no contraindications to oral administration of doxycycline hydrochloride and berberine hydrochloride.\n\nExclusion criteria: patients with pregnancy status, uterine malignant disease, hormone therapy within 3 months, glucose-6 phosphate dehydrogenase deficiency, hemolytic anemia, hypersensitivity to berberine hydrochloride or doxycycline. In addition, berberine hydrochloride has fewer oral adverse reactions, occasional nausea and vomiting, rash and drug fever, which disappear after stopping the drug. If the patient takes the wrong or missed medication, it is excluded.\n\nWithdrawal criteria: If the patient has corresponding adverse reaction symptoms, those with mild symptoms can be temporarily observed, and if the symptoms are severe, they can be transferred to the Department of Gastroenterology for diagnosis and treatment, and those who need to stop the drug will be withdrawn from this study.",[25],"2025-09-16",{"date":107,"type":30},"2025-09-18",{"date":109,"type":30},"2025-03-15",{"date":111,"type":21},"2026-12-31",{"name":113,"class":37},"The Fourth Affiliated Hospital of Zhejiang University School of Medicine"]